Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000442 · ClinicalTrials.gov registry record · Phase 4
Naltrexone for Relapse Prevention
A Phase 4 study of Alcoholism, sponsored by UConn Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT00000442 is a Phase 4 study of Alcoholism that has completed, run by UConn Health. The registered enrollment target is 57 participants, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00000442, a Phase 4 study of Alcoholism, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to evaluate the safety and effectiveness of an injectable slow releasing preparation of naltrexone to reduce alcohol consumption and risk of relapse in alcohol-dependent subjects. Individuals will receive either naltrexone or a placebo injection for a total of three months, with two subsequent followup visits spanning a 6- month period.
Conditions Studied
Interventions
- DRUG naltrexone (Revia)
Study Locations (1)
Pennsylvania
- Department of Psychiatry, University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Est. Completion | 2002-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000442
The ClinicalTrials.gov registry entry for NCT00000442 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (85% lower). The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 1 intervention - of which naltrexone (Revia) is the first listed.
NCT00000442 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00000442 about?
NCT00000442 is a clinical study titled "Naltrexone for Relapse Prevention". This study is to evaluate the safety and effectiveness of an injectable slow releasing preparation of naltrexone to reduce alcohol consumption and risk of relapse in alcohol-dependent subjects. Individuals will receive either naltrexone or a placebo injection for a total of three months, with two su...
What is the current status of trial NCT00000442?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 57 participants. Estimated completion is 2002-12.
What conditions does trial NCT00000442 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT00000442?
The interventions under investigation include: naltrexone (Revia) (DRUG).
Who is sponsoring clinical trial NCT00000442?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000442 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Naltrexone in AUD Reward Drinkers
RECRUITING · Phase 4
-
Naltrexone Treatment of Alcohol Abuse in Schizophrenia
COMPLETED · Phase 4
-
Naltrexone, Craving, and Drinking
COMPLETED · Phase 4
-
Sertraline Pharmacotherapy for Alcoholism Subtypes
COMPLETED · Phase 4
-
Naltrexone for Heavy Drinking in Young Adults
COMPLETED · Phase 4
-
Managing Alcoholism in People Who Do Not Respond to Naltrexone
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.